Alto Neuroscience (NYSE:ANRO) Stock Price Up 10% – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) was up 10% on Tuesday . The stock traded as high as $18.42 and last traded at $18.5850. Approximately 114,874 shares changed hands during trading, a decline of 44% from the average daily volume of 206,278 shares. The stock had previously closed at $16.89.

Analysts Set New Price Targets

A number of research firms recently weighed in on ANRO. BTIG Research lifted their price target on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Robert W. Baird upped their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. HC Wainwright boosted their price objective on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Jefferies Financial Group raised their price target on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus price target of $26.50.

Alto Neuroscience Trading Up 13.8%

The firm has a market cap of $597.17 million, a P/E ratio of -8.39 and a beta of 2.79. The business’s 50 day moving average is $16.96 and its 200-day moving average is $10.94. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC boosted its stake in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after acquiring an additional 12,000 shares during the period. Vanguard Group Inc. raised its holdings in shares of Alto Neuroscience by 1.9% during the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock valued at $4,444,000 after buying an additional 20,702 shares during the last quarter. Vivo Capital LLC acquired a new stake in Alto Neuroscience in the fourth quarter worth about $18,433,000. Marshall Wace LLP increased its stake in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after acquiring an additional 84,417 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Alto Neuroscience by 4.3% in the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock worth $1,269,000 after buying an additional 12,896 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.